Related Experiment Video

Updated: Aug 25, 2025

High-Throughput Cellular Profiling of Targeted Protein Degradation Compounds Using HiBiT CRISPR Cell Lines
05:33

High-Throughput Cellular Profiling of Targeted Protein Degradation Compounds Using HiBiT CRISPR Cell Lines

Published on: November 9, 2020

10.0K

Discovery of E3 Ligase Ligands for Target Protein Degradation

Jaeseok Lee1, Youngjun Lee2, Young Mee Jung1,3,4

  • 1Department of Chemistry, Kangwon National University, Chuncheon 24341, Korea.

Molecules (Basel, Switzerland)
|October 14, 2022
PubMed

Insights

New E3 ligase ligands are crucial for advancing proteolysis-targeting chimera (PROTAC) technology. This review explores diverse E3 ligase ligands to overcome limitations and enhance PROTAC therapeutic development.

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Drug Discovery

Background:

  • Target protein degradation is a key therapeutic strategy.
  • Proteolysis-targeting chimeras (PROTACs) induce protein degradation via E3 ligases.
  • Current PROTACs often rely on limited E3 ligase ligands (CRBN, VHL).

Purpose of the Study:

  • To review existing E3 ligase ligands for PROTAC development.
  • To highlight the need for diverse E3 ligase ligands.
  • To discuss applications of novel E3 ligase ligands in PROTACs.

Main Methods:

  • Literature review of E3 ligase ligands and PROTAC applications.
  • Analysis of limitations associated with CRBN and VHL ligands.
  • Exploration of emerging E3 ligase ligands.

Main Results:

  • PROTAC technology relies on induced proximity between target proteins and E3 ligases.
  • Limited E3 ligase ligand options (CRBN, VHL) restrict PROTAC efficacy and lead to resistance.
  • Discovery of novel E3 ligase ligands is essential for overcoming these limitations.

Conclusions:

  • Expanding the repertoire of E3 ligase ligands is critical for improving PROTAC technology.
  • Diverse E3 ligase ligands can enhance PROTAC efficacy and overcome resistance mechanisms.
  • Further research into novel E3 ligase ligands will drive the development of next-generation therapeutics.
Keywords:
E3 ligase ligandPROTACtarget protein degradation

More Related Videos

Evaluation of Substrate Ubiquitylation by E3 Ubiquitin-ligase in Mammalian Cell Lysates09:47

Evaluation of Substrate Ubiquitylation by E3 Ubiquitin-ligase in Mammalian Cell Lysates

Published on: May 10, 2022

2.7K
Author Spotlight: Evaluating Biophysical Assays for Characterizing PROTACS Ternary Complexes07:22

Author Spotlight: Evaluating Biophysical Assays for Characterizing PROTACS Ternary Complexes

Published on: January 12, 2024

3.6K

Related Concept Videos

Regulated Protein Degradation02:58

Regulated Protein Degradation

It is vital to regulate the activity of enzymatic as well as non-enzymatic proteins inside the cell. This can be achieved either through creating a balance between their rate of synthesis and degradation or regulating the intrinsic activity of the protein. Both these regulation mechanisms play an essential role in the normal functioning of cells.
Protein degradation plays two important roles in the cells. It helps to protect cells from misfolded or damaged proteins before they lead to a...
7.5K
The Proteasome01:13

The Proteasome

Eukaryotic cells can degrade proteins through several pathways. One of the most important among these is the ubiquitin-proteasome pathway. It helps the cell eliminate the misfolded, damaged, or unwarranted cytoplasmic proteins in a highly specific manner.
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. This involves participation of a series of enzymes including— E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
1.1K
Covalently Linked Protein Regulators02:04

Covalently Linked Protein Regulators

Proteins can undergo many types of post-translational modifications, often in response to changes in their environment. These modifications play an important role in the function and stability of these proteins. Covalently linked molecules include functional groups, such as methyl, acetyl, and phosphate groups, and also small proteins, such as ubiquitin. There are around 200 different types of covalent regulators that have been identified.
These groups modify specific amino acids in a protein....
6.9K
Export of Misfolded Proteins out of the ER01:32

Export of Misfolded Proteins out of the ER

After folding, the ER assesses the quality of secretory and membrane proteins. The correctly folded proteins are cleared by the calnexin cycle for transport to their final destination, while misfolded proteins are held back in the ER lumen. The ER chaperones attempt to unfold and refold the misfolded proteins but sometimes fail to achieve the correct native conformation. Such terminally misfolded proteins are then exported to the cytosol by ER-associated degradation or ERAD pathway for...
3.8K
Receptor Downregulation in MVBs01:15

Receptor Downregulation in MVBs

Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that  lead to cell proliferation, migration, and differentiation. Overexpression of EGFR  stimulates cells to proliferate. Excessive  EGFR...
2.1K